MGNX
MacroGenics (MGNX)
$43
About MacroGenics (MGNX)
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Details
Daily high
$1.60
Daily low
$1.42
Price at open
$1.56
52 Week High
$5.77
52 Week Low
$0.99
Market cap
90.2M
Dividend yield
0.00%
Volume
264,175
Avg. volume
606,717
P/E ratio
-1.33
MacroGenics News
Details
Daily high
$1.60
Daily low
$1.42
Price at open
$1.56
52 Week High
$5.77
52 Week Low
$0.99
Market cap
90.2M
Dividend yield
0.00%
Volume
264,175
Avg. volume
606,717
P/E ratio
-1.33